Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations

Published on Jul 1, 2019in The Lancet Respiratory Medicine22.99
· DOI :10.1016/S2213-2600(19)30144-4
Juncheng Dai31
Estimated H-index: 31
(Nanjing Medical University),
Jun Lv15
Estimated H-index: 15
(PKU: Peking University)
+ 43 AuthorsHongbing Shen51
Estimated H-index: 51
(Nanjing Medical University)
Summary Background Genetic variation has an important role in the development of non-small-cell lung cancer (NSCLC). However, genetic factors for lung cancer have not been fully identified, especially in Chinese populations, which limits the use of existing polygenic risk scores (PRS) to identify subpopulations at high risk of lung cancer for prevention. We therefore aimed to identify novel loci associated with NSCLC risk, and generate a PRS and evaluate its utility and effectiveness in the prediction of lung cancer risk in Chinese populations. Methods To systematically identify genetic variants for NSCLC risk, we newly genotyped 19 546 samples from Chinese NSCLC cases and controls from the Nanjing Medical University Global Screening Array Project and did a meta-analysis of genome-wide association studies (GWASs) of 27 120 individuals with NSCLC and 27 355 without NSCLC (13 327 cases and 13 328 controls of Chinese descent as well as 13 793 cases and 14 027 controls of European descent). We then built a PRS for Chinese populations from all reported single-nucleotide polymorphisms that have been reported to be associated with lung cancer risk at genome-wide significance level. We evaluated the utility and effectiveness of the generated PRS in predicting subpopulations at high-risk of lung cancer in an independent prospective cohort of 95 408 individuals from the China Kadoorie Biobank (CKB) with more than 10 years' follow-up. Findings We identified 19 susceptibility loci to be significantly associated with NSCLC risk at p≤5·0 × 10 −8 , including six novel loci. When applied to the CKB cohort, the PRS of the risk loci successfully predicted lung cancer incident cases in a dose-response manner in participants at a high genetic risk (top 10%) than those at a low genetic risk (bottom 10%; adjusted hazard ratio 1·96, 95% CI 1·53–2·51; p trend =2·02 × 10 −9 ). Specially, we observed consistently separated curves of lung cancer events in individuals at low, intermediate, and high genetic risk, respectively, and PRS was an independent effective risk stratification indicator beyond age and smoking pack-years. Interpretation We have shown for the first time that GWAS-derived PRS can be effectively used in discriminating subpopulations at high risk of lung cancer, who might benefit from a practically feasible PRS-based lung cancer screening programme for precision prevention in Chinese populations. Funding National Natural Science Foundation of China, the Priority Academic Program for the Development of Jiangsu Higher Education Institutions, National Key R&D Program of China, Science Foundation for Distinguished Young Scholars of Jiangsu, and China's Thousand Talents Program.
  • References (40)
  • Citations (1)
#1Cheng Wang (Nanjing Medical University)H-Index: 13
#2Rong Yin (Nanjing Medical University)H-Index: 17
Last.Tao Jiang (Nanjing Medical University)H-Index: 5
view all 26 authors...
#1Freddie Ian Bray (IARC: International Agency for Research on Cancer)H-Index: 81
#2Jacques Ferlay (IARC: International Agency for Research on Cancer)H-Index: 61
Last.Ahmedin Jemal (ACS: American Cancer Society)H-Index: 100
view all 6 authors...
#1Ali Torkamani (Scripps Research Institute)H-Index: 36
#2Nathan E. Wineinger (Scripps Research Institute)H-Index: 15
Last.Eric J. Topol (Scripps Research Institute)H-Index: 175
view all 3 authors...
#1Douglas E. Wood (UW: University of Washington)H-Index: 39
#2Ella A. Kazerooni (UM: University of Michigan)H-Index: 67
Last.Rudy P. LacknerH-Index: 19
view all 33 authors...
#1Rui Pan (Nanjing Medical University)H-Index: 1
#2Meng Zhu (Nanjing Medical University)H-Index: 12
Last.Zhengming Chen (Clinical Trial Service Unit)H-Index: 46
view all 12 authors...
#1James D. McKay (IARC: International Agency for Research on Cancer)H-Index: 50
#2Rayjean J. Hung (U of T: University of Toronto)H-Index: 45
Last.Yafang Li (Dartmouth College)H-Index: 10
view all 140 authors...
#1Rahul S. Desikan (UCSF: University of California, San Francisco)H-Index: 30
#2Chun Chieh Fan (University of California, Berkeley)H-Index: 2
Last.Dominic Holland (University of California, Berkeley)H-Index: 36
view all 34 authors...
#1Juncheng Dai (Nanjing Medical University)H-Index: 31
#2Wei Shen (Nanjing Medical University)H-Index: 7
Last.Lian Li (Tianjin Medical University)H-Index: 5
view all 28 authors...